November 13-14, 2019 - Het Pand, University of Ghent, Belgium

2nd Conference on Next Generation Sequencing
for Adventitious Virus Detection in
Human and Veterinary Biologics

An IABS-EU Meeting

Read the Meeting Report


Meeting objectives
his meeting will focus on the current scientific data and knowledge related to the use of next generation sequencing technologies for adventitious virus detection in biological products. Discussions will include ongoing efforts and future needs toward standardization and validation of the technical and bioinformatics steps involved in NGS for its applications in characterization and safety evaluation of biologics, including human and animal vaccines. The meeting will bring together representatives from industry, academia, technology providers, and international regulatory bodies for developing a scientific consensus regarding readiness of NGS for detection of adventitious viruses in biologics.


Scientific Committee

Dieter Deforce, Ghent University / Federal Agency for Medicines and Health Products of Belgium (FAMHP)
Sebastiaan Theuns, Ghent University / PROVAXS 
Arifa Khan, U.S. Food and Drug Administration (FDA)
Pieter Neels, International Alliance for Biological Standardization (IABS)
Sven Arnouts, Ghent University / PROVAXS
Johannes Blümel, Paul-Ehrlich Institut (PEI)
William Egan, GlaxoSmithKline Vaccines
Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Ivana Knezevic, World Heath Organization (WHO)
Laurent Mallet, Sanofi Pasteur
Gerald Schumann, Paul-Ehrlich Institut (PEI)
Joseph Victoria, Boehringer-Ingelheim

Register Here




International Alliance for Biological Standardization

Twitter Feed

Examples of networks to address transdisciplinary issues related to infectious disease prevention and vaccine devel…
#IABS 65 conference on Infectious diseases, LYON. John Edmunds (London School of Tropical Hygiene & Medicine): Real…
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.